Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5572-5584

  Jerby, Livnat ^a   Ruppin, Eytan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LACTATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE; TORCETRAPIB;

ACCURACY; ANAEROBIC METABOLISM; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CANCER LOCALIZATION; CANCER MODEL; CARDIOVASCULAR DISEASE; CELL METABOLISM; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; GENETIC MODEL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEIOMYOMATOSIS; MALIGNANT NEOPLASTIC DISEASE; METABOLIC CAPACITY; PREDICTION; PRIORITY JOURNAL; REVIEW; STRUCTURAL BIOINFORMATICS;

CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867554554     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1856     Document Type: Review

References (82)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012;21:297-308.
3. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85-95.
4. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring bene fi ts on cancer cells. Clin Cancer Res 2012;18:5554-61.
5. Miller DM, Thomas SD, Islam A, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res 2012;18:5546-53.
6. Prendergast GC. Cancer: why tumours eat tryptophan. Nature 2011;478:192-4.
7. Sotgia F, Martinez-Outschoorn U, Lisanti M. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med 2011;9:62.
8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
9. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008;134:703-7.
10. Mullen AR, Wheaton WW, Jin ES, Chen P-H, Sullivan LB, Cheng T, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012;481:385-8.
11. Metallo CM, Gameiro PA, Bell EL, Mattaini KR, Yang J, Hiller K, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2011;481:380-4.
12. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006;25:4675-82. (Pubitemid 44187617)
13. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010;16:387-97.
14. Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012;18:5562-71.
15. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011;10:671-84.
16. Meijer TWH, Kaanders JHAM, Span PN, Bussink J. Targeting hypoxia, HIF-1 and tumor glucose metabolismto improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585-94.
17. Papp B, Notebaart RA, Pál C. Systems-biology approaches for predicting genomic evolution. Nat Rev Genet 2011;12:591-602.
18. Wessely F, Bartl M, Guthke R, Li P, Schuster S, Kaleta C. Optimal regulatory strategies for metabolic pathways in Escherichia coli depending on protein costs. Mol Syst Biol 2011;7:515.
19. Trawick JD, Schilling CH. Use of constraint-based modeling for the prediction and validation of antimicrobial targets. Biochem Pharmacol 2006;71:1026-35.
20. Deutscher D, Meilijson I, Kupiec M, Ruppin E. Multiple knockout analysis of genetic robustness in the yeast metabolic network. Nat Genet 2006;38:993-8. (Pubitemid 44334827)
21. Burgard AP, Pharkya P, Maranas CD. Optknock: a bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnol Bioeng 2003;84:647-57. (Pubitemid 37420336)
22. Folger O, Jerby L, Frezza C, Gottlieb E, Ruppin E, Shlomi T. Predicting selective drug targets in cancer through metabolic networks. Mol Syst Biol 2011;7:501.
23. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci U S A 2007;104:1777-82. (Pubitemid 46239855)
24. Shlomi T, Cabili MN, Ruppin E. Predicting metabolic biomarkers of human inborn errors of metabolism. Mol Syst Biol 2009;5:263.
25. Jerby L, Shlomi T, Ruppin E. Computational reconstruction of tissue-specific metabolic models: application to human liver metabolism. Mol Syst Biol 2010;6:401.
26. Locasale Jason W, Cantley Lewis C. Metabolic flux and the regulation of mammalian cell growth. Cell Metab 2011;14:443-51.
27. Garfinkel D, Hess B. Metabolic control mechanisms. VII.A detailed computer model of the glycolytic pathway in ascites cells. J Biol Chem 1964;239:971-83.
28. Lee I-D, Palsson BO. A comprehensive model of human erythrocyte metabolism: extensions to include pH effects. Biomed Biochim Acta 1991;49:771-89.
29. Bakker B, van Eunen K, Jeneson JA, van Riel NA, Bruggeman FJ, Teusink B. Systems biology from micro-organisms to human metabolic diseases: the role of detailed kinetic models. Biochem Soc Trans 2010;38:1294-301.
30. Varma A, Palsson BO. Metabolic flux balancing: basic concepts, scientific and practical use. Nature Biotechnol 1994;12:994-8.
31. Yizhak K, Benyamini T, Liebermeister W, Ruppin E, Shlomi T. Integrating quantitative proteomics and metabolomics with a genome-scale metabolic network model. Bioinformatics 2010;26:i255-60.
32. Shlomi T, Cabili MN, Herrgard MJ, Palsson BO, Ruppin E. Network-based prediction of human tissue-specific metabolism. Nat Biotechnol 2008;26:1003-10.
33. Jerby L, Wolf L, Denkert C, Stein GY, Hilvo M, Oresic M, et al. Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer. Cancer Res 2012 Sep 17. [Epub ahead of print].
34. Lewis NE, Nagarajan H, Palsson BO. Constraining the metabolic genotype-phenotype relationship using a phylogeny of in silico methods. Nat Rev Microbiol 2012;10:291-305.
35. Ruppin E, Papin JA, de Figueiredo LF, Schuster S. Metabolic reconstruction, constraint-based analysis and game theory to probe genome-scale metabolic networks. Curr Opin Biotechnol 2010;21:502-10.
36. Bordbar A, Palsson BO. Using the reconstructed genome-scale human metabolic network to study physiology and pathology. J Intern Med 2012;271:131-41.
37. Orth JD, Thiele I, Palsson BO. What is flux balance analysis? Nat Biotechnol 2010;28:245-8.
38. Agren R, Bordel S, Mardinoglu A, Pornputtapong N, Nookaew I, Nielsen J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. PLoS Comput Biol 2012;8:e1002518.
39. Becker SA, Palsson BO. Context-specific metabolic networks are consistent with experiments. PLoS Comput Biol 2008;4:e1000082.
40. Colijn C, Brandes A, Zucker J, Lun DS, Weiner B, Farhat MR, et al. Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. PLoS Comput Biol 2009;5:e1000489.
41. Jensen PA, Papin JA. Functional integration of a metabolic network model and expression data without arbitrary thresholding. Bioinformatics 2011;27:541-7.
42. Shlomi T, Berkman O, Ruppin E. Regulatory on/off minimization of metabolic flux changes after genetic perturbations. Proc Natl Acad Sci U S A 2005;102:7695-700. (Pubitemid 40741033)
43. Segrè D, Vitkup D, Church GM. Analysis of optimality in natural and perturbed metabolic networks. Proc Natl Acad Sci U S A 2002;99:15112-7. (Pubitemid 35334618)
44. Mahadevan R, Schilling CH. The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. Metab Eng 2003;5:264-76. (Pubitemid 38122488)
45. Schellenberger J, Palsson BØ. Use of randomized sampling for analysis of metabolic networks. J Biol Chem 2009;284:5457-61.
46. Chandrasekaran S, Price ND. Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 2010;107:17845-50.
47. Heinemann M, Sauer U. Systems biology of microbial metabolism. Curr Opin Microbiol 2010;13:337-43.
48. Wiback SJ, Palsson BO. Extreme pathway analysis of human red blood cell metabolism. Biophys J 2002;83:808-18. (Pubitemid 34803618)
49. Vo TD, Greenberg HJ, Palsson BO. Reconstruction and functional characterization of the human mitochondrial metabolic network based on proteomic and biochemical data. J Biol Chem 2004;279:39532-40. (Pubitemid 39258220)
50. Chatziioannou A, Palaiologos G, Kolisis FN. Metabolic flux analysis as a tool for the elucidation of the metabolism of neurotransmitter glutamate. Metab Eng 2003;5:201-10. (Pubitemid 37124119)
51. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, et al. The Edinburgh human metabolic network reconstruction and its functional analysis. Mol Syst Biol 2007;3:135.
52. Romero P, Wagg J, Green M, Kaiser D, Krummenacker M, Karp P. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 2004;6:R2.
53. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008;36 Suppl 1:D480-4. (Pubitemid 351149770)
54. Zelezniak A, Pers TH, Soares So, Patti ME, Patil KR. Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes. PLoS Comput Biol 2010;6:e1000729.
55. Gille C, Bolling C, Hoppe A, Bulik S, Hoffmann S, Hubner K, et al. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol Syst Biol 2010;6:411.
56. Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol 2010;6:e1000938.
57. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol 2010;28:1279-85.
58. Bordbar A, Lewis NE, Schellenberger J, Palsson BO, Jamshidi N. Insight into human alveolar macrophage and M. tuberculosis interactions via metabolic reconstructions. Mol Syst Biol 2010;6:422.
59. Bordbar A, Feist A, Usaite-Black R, Woodcock J, Palsson B, Famili I. A multi-tissue type genome-scale metabolic network for analysis of whole-body systems physiology. BMC Syst Biol 2011;5:180.
60. Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 2011;477:225-8.
61. Resendis-Antonio O, Checa A, Encarnación S. Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect. PLoS One 2010;5:e12383.
62. Vazquez A, Liu J, Zhou Y, Oltvai Z. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC Syst Biol 2010;4:58.
63. Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol 2011;7:e1002018.
64. Kim HU, Sohn SB, Lee SY. Metabolic network modeling and simulation for drug targeting and discovery. Biotechnol J 2012;7:330-42.
65. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997;278:1064-8. (Pubitemid 27517876)
66. Hartman JL, Garvik B, Hartwell L. Principles for the buffering of genetic variation. Science 2001;291:1001-4.
67. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
68. Eisenberg T, Knauer H, Schauer A, Buttner S, Ruckenstuhl C, Carmona-Gutierrez D, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 2009;11:1305-14.
69. Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyl-transferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 2000;19:6584-93. (Pubitemid 32197696)
70. Schneider C, Pozzi A. Cyclooxygenases and lipoxygenases in cancer. Cancer Metastasis Rev 2011;30:277-94.
71. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 2003;4:565-85. (Pubitemid 37139050)
72. Dudakovic A, Tong H, Hohl R. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Invest New Drugs 2011;29:912-20.
73. Eruslanov E, Kaliberov S, Daurkin I, Kaliberova L, Buchsbaum D, Vieweg J, et al. Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009;182:7548-57.
74. Li L, Zhou X, Ching W-K, Wang P. Predicting enzymetargets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines.BMC Bioinformatics 2010;11:501.
75. Davis VW, Bathe OF, Schiller DE, Slupsky CM, Sawyer MB. Metabolomics and surgical oncology: potential role for small molecule biomarkers. J Surg Oncol 2011;103:451-9.
76. Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin Cancer Res 2012;18:5537-45.
77. Zheng Q-H, Stone KL, Mock BH, Miller KD, Fei X, Liu X, et al. [11C]choline as a potential PET marker for imaging of breast cancer athymic mice. Nucl Med Biol 2002;29:803-7. (Pubitemid 35346900)
78. Covert MW, Xiao N, Chen TJ, Karr JR. Integrating metabolic, transcriptional regulatory and signal transduction models in Escherichia coli. Bioinformatics 2008;24:2044-50.
79. Min Lee J, Gianchandani EP, Eddy JA, Papin JA. Dynamic analysis of integrated signaling, metabolic, and regulatory networks. PLoS Comput Biol 2008;4:e1000086.
80. Ishii N, Nakahigashi K, Baba T, Robert M, Soga T, Kanai A, et al. Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science 2007;316:593-7. (Pubitemid 46683144)
81. Sutendra G, Michelakis ED. Reversing the Warburg effect: metabolic modulation as a novel cancer therapy mitochondria and cancer. [cited 2012 Sep 26]. Available at: http://stm.sciencemag.org/content/3/94/94ra70.abstract.
82. Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med 2011;3:94ra70.